Most recently, a phase 1 trial investigating the Menin-inhibitor Revumenib (SNDX-5613) in KMT2A-r and NPM1c AML reported on emergence of MEN1 mutations mediating resistance in 38.7% of patients [33]. This evidence concerns the gene MEN1 and acute myeloid leukemia.